About Author: Vishal Goel, Managing Director, Rx Propellant has a rich experience of two decades in real estate advisory, strategy and life sciences industry. As the MD and Head of Alexandria India operations, he deployed over USD 200 million and personally managed development of over 1 million square feet of Lifesciences real estate assets. He has been instrumental in conceptualizing and developing ‘Genome Valley’ cluster in Hyderabad city.
Global healthcare is developing expeditiously with digital health technologies and tailored therapeutics leading the charge. These innovations enhance accessibility and efficiency, offering personalized care and reducing costs worldwide. In India, initiatives like the National Digital Health Mission, Unique Methods of Management and Treatment of Inherited Disorders (2019), and the Genome India Project (2020), are contributing to the development of targeted medicines and bridging gaps in healthcare.
India’s emphasis on innovation and strengthening public health systems is being driven by adopting global technological advancements, strategic investments, and a growing focus on patient-centric care, making India’s healthcare and life science sectors shift gears. Central to this change is integrated laboratory and clinical services, which improve and optimize the precision of healthcare delivery, particularly personalized therapies.
Through integrated lab-clinic facilities offered by select life sciences real estate players in India, life science enterprises, especially the biopharmaceutical sector can optimize the development and delivery of personalized therapies, advancing innovation and improving patient outcomes.
